1.Efficiency analysis of stenting for acute colorectal obstruction.
Na-Na ZHANG ; Peng LI ; Shu-Tian ZHANG
Chinese Medical Journal 2013;126(21):4189-4191
Adult
;
Aged
;
Aged, 80 and over
;
Female
;
Hospital Costs
;
Humans
;
Intestinal Obstruction
;
surgery
;
Male
;
Middle Aged
;
Postoperative Complications
;
Stents
;
adverse effects
;
economics
2.Cost-Effectiveness of Drug-Eluting vs. Bare-Metal Stents in Patients with Coronary Artery Disease from the Korean National Health Insurance Database.
Soojin LEE ; Kyungwon BAEK ; Kihong CHUN
Yonsei Medical Journal 2014;55(6):1533-1541
PURPOSE: The aim of this study was to evaluate the cost-effectiveness of the use of drug-eluting stents (DESs), as compared with bare-metal stents (BMSs) in Korea. MATERIALS AND METHODS: A retrospective cohort study was conducted between January 2000 and December 2007. Subjects were stent-treated for the first time between 2004 and 2005, with four years of follow-up (2004-2007) (n=43674). The incremental cost-effectiveness ratio (ICER) was used to calculate the costs of DESs compared with BMSs among patients with coronary artery disease (CAD). Cost-effectiveness was assessed with effectiveness defined as a reduction in major adverse cardiac events after six months and after one, two, three, and four years. RESULTS: The total costs of a DESs were 674108 Korean won (KRW) higher than that of a BMSs at the end of the follow-up; 13635 thousand KRW per patient treated with DESs and 12960 thousand KRW per patient treated with BMSs. The ICER was 256315 per KRW/death avoided and 293090 per KRW/re-stenting avoided among the CAD patients at the end of the follow-up. CONCLUSION: The ICER for the high-risk patients was lower than that for the low-risk patients. The use of DESs is clinically more useful than the use of BMSs for CAD and myocardial infarction patients, especially for those considered to be high-risk patients in Korea.
Aged
;
*Angioplasty, Balloon, Coronary
;
Asian Continental Ancestry Group/statistics & numerical data
;
Coronary Artery Disease/etiology/*therapy
;
Cost-Benefit Analysis
;
Drug-Eluting Stents/economics
;
Female
;
Humans
;
Immunosuppressive Agents/administration & dosage/*economics
;
Male
;
Middle Aged
;
Myocardial Infarction/therapy
;
National Health Programs/*statistics & numerical data
;
Paclitaxel/administration & dosage
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Risk
;
Sirolimus/administration & dosage
;
Stents/adverse effects/*economics
;
Treatment Outcome